These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 21135277

  • 1. Taming glioblastoma by targeting angiogenesis: 3 years later.
    Wong ET, Brem S.
    J Clin Oncol; 2011 Jan 10; 29(2):124-6. PubMed ID: 21135277
    [No Abstract] [Full Text] [Related]

  • 2. Neuro-oncology: What is the optimal use of bevacizumab in glioblastoma?
    Desjardins A.
    Nat Rev Neurol; 2015 Aug 10; 11(8):429-30. PubMed ID: 26195258
    [No Abstract] [Full Text] [Related]

  • 3. Avastin: more questions than answers. .
    Desjardins A, Sampson JH.
    J Neurosurg; 2012 Feb 10; 116(2):336-40; discussion 340. PubMed ID: 22035270
    [No Abstract] [Full Text] [Related]

  • 4. AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme.
    Chinot OL, de La Motte Rouge T, Moore N, Zeaiter A, Das A, Phillips H, Modrusan Z, Cloughesy T.
    Adv Ther; 2011 Apr 10; 28(4):334-40. PubMed ID: 21432029
    [Abstract] [Full Text] [Related]

  • 5. Taming glioblastoma: targeting angiogenesis.
    Wong ET, Brem S.
    J Clin Oncol; 2007 Oct 20; 25(30):4705-6. PubMed ID: 17947716
    [No Abstract] [Full Text] [Related]

  • 6. [Retrospective analysis of 24 recurrent glioblastoma after chemoradiation and treated with nitrosoureas or irinotecan and bevacizumab].
    Vauleon E, Mesbah H, Gedouin D, Lecouillard I, Louvel G, Hamlat A, Riffaud L, Carsin B, Quillien V, Audrain O, Lesimple T.
    Bull Cancer; 2012 Feb 01; 99(2):121-6. PubMed ID: 22257744
    [Abstract] [Full Text] [Related]

  • 7. [Association of radiotherapy and chemotherapy-targeted therapies in glioblastomas].
    Laigle-Donadey F, Dehais C, Mazeron JJ, Sanson M.
    Bull Cancer; 2009 Mar 01; 96(3):291-7. PubMed ID: 19318307
    [Abstract] [Full Text] [Related]

  • 8. Clinical benefit in recurrent glioblastoma from adjuvant NovoTTF-100A and TCCC after temozolomide and bevacizumab failure: a preliminary observation.
    Wong ET, Lok E, Swanson KD.
    Cancer Med; 2015 Mar 01; 4(3):383-91. PubMed ID: 25620708
    [Abstract] [Full Text] [Related]

  • 9. Reply to T.J. Kruser et al.
    Chinot OL, Taphoorn MJ, Bais C, Bourgon R, Phillips HS, Abrey LE, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Cloughesy T.
    J Clin Oncol; 2016 Apr 10; 34(11):1282-3. PubMed ID: 26884575
    [No Abstract] [Full Text] [Related]

  • 10. Fewer dollars, more sense.
    Garfield DH, Hercbergs A.
    J Clin Oncol; 2008 Nov 10; 26(32):5304-5; author reply 5305. PubMed ID: 18854564
    [No Abstract] [Full Text] [Related]

  • 11. Similar Trials With Differing Outcomes: Reconciliation in Glioblastoma.
    Chamberlain MC.
    J Clin Oncol; 2016 Jan 20; 34(3):291-2. PubMed ID: 26628477
    [No Abstract] [Full Text] [Related]

  • 12. Bevacizumab antiangiogenic therapy for glioblastoma.
    Junck L.
    Neurology; 2011 Feb 01; 76(5):414-5. PubMed ID: 21282587
    [No Abstract] [Full Text] [Related]

  • 13. Identification of Patients Who Benefit From Bevacizumab in High-Grade Glioma-An Easy Question Turned Difficult: Treat the Scan or the Patient?
    Kruser TJ, Mehta MP, Kozak KR.
    J Clin Oncol; 2016 Apr 10; 34(11):1281-2. PubMed ID: 26884565
    [No Abstract] [Full Text] [Related]

  • 14. Enigma of a rapid introduction of antiangiogenic therapy with bevacizumab in glioblastoma: a new era in the treatment of malignant brain tumours?
    Henriksson R, Bergström P, Johansson M, Sandström M.
    Acta Oncol; 2009 Apr 10; 48(1):6-8. PubMed ID: 18932097
    [No Abstract] [Full Text] [Related]

  • 15. Bevacizumab and recurrent malignant gliomas: a European perspective.
    Wick W, Weller M, van den Bent M, Stupp R.
    J Clin Oncol; 2010 Apr 20; 28(12):e188-9; author reply e190-2. PubMed ID: 20159801
    [No Abstract] [Full Text] [Related]

  • 16. [Our experience with targeted therapy in glioblastoma multiforme].
    Kiss E, Lahm E, Vachaja J, Nagy P, Bazsó P, Fekete Z, Takácsi-Nagy Z, Pápai Z.
    Magy Onkol; 2013 Dec 20; 57(4):264-8. PubMed ID: 24353992
    [Abstract] [Full Text] [Related]

  • 17. Treatment of children with glioblastoma with conformal radiation, temozolomide, and bevacizumab as adjuncts to surgical resection.
    Friedman GK, Spiller SE, Harrison DK, Fiveash JB, Reddy AT.
    J Pediatr Hematol Oncol; 2013 Apr 20; 35(3):e123-6. PubMed ID: 23425999
    [Abstract] [Full Text] [Related]

  • 18. Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours.
    Koumarianou A, Antoniou S, Kanakis G, Economopoulos N, Rontogianni D, Ntavatzikos A, Tsavaris N, Pectasides D, Dimitriadis G, Kaltsas G.
    Endocr Relat Cancer; 2012 Feb 20; 19(1):L1-4. PubMed ID: 22232542
    [No Abstract] [Full Text] [Related]

  • 19. Reply to M.C. Chamberlain.
    Taphoorn MJ.
    J Clin Oncol; 2016 Jan 20; 34(3):292. PubMed ID: 26628468
    [No Abstract] [Full Text] [Related]

  • 20. American Society of Clinical Oncology-39th Annual Meeting. Angiogenesis. 31 May-3 June 2003, Chicago, IL, USA.
    Erlich R, Durrance A.
    IDrugs; 2003 Jul 20; 6(7):623-4. PubMed ID: 12906003
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.